11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer
作者
Josep M. Tabernero,Robin M.J.M. van Geel,J. C. Bendell,Anna Spreafico,Martin Schüler,T. Yoshino,Jean‐Pierre Delord,Yasuhide Yamada,Martijn P. Lolkema,Jason Edward Faris,F. Eskens,Sachit Sharma,Rona D. Yaeger,Heinz Joseph Lenz,Zev A. Wainberg,Emin Avşar,Arkendu Chatterjee,Savina A. Jaeger,Tim Demuth,Jan H.M. Schellens